Enhanced Permeability and Retention effect: Difference between revisions
No edit summary |
No edit summary |
||
| Line 11: | Line 11: | ||
{{SIB}} | {{SIB}} | ||
[[Category: Tumors]] | |||
{{WH}} | {{WH}} | ||
{{WikiDoc Sources}} | {{WikiDoc Sources}} | ||
Revision as of 15:51, 7 May 2009
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
The Enhanced Permeability and Retention (EPR) effect is the property by which certain sizes of molecules, typically liposomes or macromolecular drugs, tend to accumulate in tumor tissue much more than they do in normal tissues1,2,3. The general explanation that is given for this phenomenon is that, in order for tumor cells to grow quickly, they must stimulate the production of blood vessels (VEGF).Tumor cell aggregates of size as small as 150-200 um, start to become dependent on blood supply carried out by neovasculature for their nutritional and oxygen supply . This newly formed tumor vessels are usually abnormal in form and architecture. They are poorly aligned defective endothelial cells with wide fenestration, lacking smooth muscle layer, or inervation with wider lumen, and impaired functional receptors for angiotensin II. Furthermore, tumor tissues usually lack effective lymphatic drainage . All these factors will lead to abnormal molecular and fluid transport dynamics especially for macromolecular drugs. Namely, this phenomenon was coined “enhanced permeability and retention (EPR)-effect” of macromolecules and lipids in solid tumors . The EPR-effect is even more enhanced by great many pathophysiological factors involved in enhancement of extravasation of macromolecules in solid tumor tissues. For instance, bradykinin, nitric oxide / peroxynitrite, prostaglandins, vascular permeability factor (also known as vascular endothelial growth factor VEGF), tumor necrosis factor and others .
1. Matsamura Y., Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanisms of tumoritropic accumulation of protein and the antitumor agent SMANCS. Cancer Res., 46: 6387-6392, 1986.
2. Duncan R., Sat Y-N. Tumour targeting by enhanced permeability and retention (EPR) effect. Ann. Oncol., 9 (Suppl.2): 39 1998
3. Vasey P. A., Kaye S. B., Morrison R., Twelves C., Wilson P., Duncan R., Thomson A. H., Murray L. S., Hilditch T. E., Murray T., Burtles S., Fraier D., Frigerio E., Cassidy J. Phase I clinical and pharmacokinetic study of PK1 (HPMA copolymer doxorubicin): first member of a new class of chemotherapeutic agents-drug-polymer conjugates. Clin. Cancer Res., 5: 83-94, 1999